MarketLens

What's Driving AnaptysBio's Strategic Spin-Off

6 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Aptiv's Strategic Pivot: Why the Versigent Spin-Off

6 months ago

What's Behind the Recent Insider Selling at AnaptysBio

5 months ago

What's Driving Genuine Parts Company's Bold Spin-Off Strategy

6 months ago

Is Medtronic's MiniMed Spin-Off a Smart Bet for Investors

6 months ago

Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s

Eli Lilly's immunology portfolio is gaining ground with steady revenue growth, pipeline expansion, and acquisitions, broadening its next wave of growth beyond GLP-1s.

GLP

Stock News•6 days ago

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

Spyre's SPY003 (anti-IL-23) met its primary endpoint in the SKYLINE trial, showing a statistically significant 10.0-point reduction (p<0.05). The result completes proof-of-concept for all three compon...

IBD

Stock News•1 months ago

AnaptysBio: The Royalty Waterfall Is About To Reverse

AnaptysBio's value now hinges on Jemperli royalties from GSK, with a 95% targeted EBIT margin and over $140M net cash. Royalty retention will rise after the Sagard obligation is paid by mid-2027.

ANAB

Breaking News

Low Volatility Factor

Startup Funding

Top Headlines

View More →

Stock News•29 minutes ago

Samsung backs Nvidia AI chip rival in $230 million funding round as GPU alternatives boom

Stock News•1 hour ago

Why the Market Dipped But Microsoft (MSFT) Gained Today

Stock News•1 hour ago

Microsoft Just Made a Move That Could Put More Pressure on Its Azure Business. Here's Why It Could Turn Out Great for the Stock

Stock News•1 hour ago

Nasdaq Tests Key Level On AI Warnings Ahead Of Fed Meeting; Nvidia, Sandisk, Micron Tumble

Stock News•2 hours ago

What's Driving AnaptysBio's Strategic Spin-Off

Exclusive Content for Pro Members

Related Articles

Aptiv's Strategic Pivot: Why the Versigent Spin-Off

What's Behind the Recent Insider Selling at AnaptysBio

What's Driving Genuine Parts Company's Bold Spin-Off Strategy

Is Medtronic's MiniMed Spin-Off a Smart Bet for Investors

Category

You may also like

Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

AnaptysBio: The Royalty Waterfall Is About To Reverse

Breaking News

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Top Headlines

Samsung backs Nvidia AI chip rival in $230 million funding round as GPU alternatives boom

Why the Market Dipped But Microsoft (MSFT) Gained Today

Microsoft Just Made a Move That Could Put More Pressure on Its Azure Business. Here's Why It Could Turn Out Great for the Stock

Nasdaq Tests Key Level On AI Warnings Ahead Of Fed Meeting; Nvidia, Sandisk, Micron Tumble

Trump phones Nvidia's Huang at All-In Summit, calls data center opposition a ‘hoax'